Company Information
Industry 科学研究和技术服务业
Company Introduction 江苏集萃药康生物科技股份有限公司(GemPharmatechCo.,Ltd,股票代码:688046)创立于2017年,是一家专注于实验动物小鼠模型研发、生产及非临床研究服务的国家级高新技术企业,同时是科技部认定的国家遗传工程小鼠资源库共建单位。依托CRISPR/Cas9、ES打靶等在内的基因编辑技术,公司建立了国际一流的基因修饰动物模型研发平台,拥有近3万种自主知识产权的基因工程小鼠模型品系,其中包括基因敲除/条件性敲除小鼠品系("斑点鼠计划")、药靶基因人源化模型、复杂疾病模型、系列免疫缺陷小鼠品系、无菌小鼠品系以及用于抗体药物发现的NeoMab?全人源抗体转基因小鼠,为全球科研机构、CRO公司及医药企业提供全面的模型资源支持。公司提供从基因编辑定制(包括转基因TG、基因敲除KO、基因敲入KI及点突变PM等)、模型繁育到功能药效分析的全流程一站式服务,服务范围涵盖肿瘤、自身免疫性疾病、代谢心血管疾病、神经退行性疾病、感染性疾病及罕见病等重点疾病领域,具体包括靶点验证、药效学评价和非GLP安全性评价等临床前研究。集萃药康致力于成为全球实验动物模型领域的领导者,通过持续深化基因编辑技术的创新应用和资源整合,为生命科学研究和生物医药产业提供高质量的动物模型和技术服务,推动人类健康事业发展。
Main Business 从事实验动物小鼠模型的研发、生产、销售及相关技术服务
Legal Representative 赵静
Top Executives
董事长:高翔
董事:柳丹,杨民民,冷德嵘,赵静
独立董事:刘俊,黄欣琪,李子翀
Top 5 Shareholder
Shareholder name Nature Holding Date
南京老岩创业投资合伙企业(有限合伙)流通A股47.86%30/09/2026
中国工商银行股份有限公司-中欧医疗健康混合型证券投资基金流通A股3.33%30/09/2026
香港中央结算有限公司流通A股3.13%30/09/2026
中国工商银行股份有限公司-诺安先锋混合型证券投资基金流通A股2.88%30/09/2026
江苏省产业技术研究院有限公司流通A股2.71%30/09/2026
Company Secretary 王逸鸥
Solicitors 江苏世纪同仁律师事务所
Auditors 致同会计师事务所(特殊普通合伙)
Tel No 025-58243997
Fax No 025-58265927
Website www.gempharmatech.com
Email ir@gempharmatech.com
Company Address
Register: 江苏省南京市江北新区学府路12号
Office: 江苏省南京市江北新区学府路12号
Listing Date 25/04/2022
Shares Capital
Shares Capital: 410,186,200
Total A Share: 410,186,200
Listed A Share: 410,186,200
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.350
DPS(RMB)* ¥ 0.220
NBV Per Share(RMB)* ¥ 5.432
Market Capitalization(RMB) 12.269B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.